Bioinfra Co Ltd
199730
Company Profile
Business description
Bioinfra Co Ltd includes bioequivalence testing of generic drugs, Phase 1 clinical trials for improved new drugs, regulatory approval clinical trials, immunoassays, and pharmaceutical quality testing.
Contact
120 Heungdeokjungang-ro
4th and 5th Floors
Giheung-gu, Yongin-si
Gyeonggi-do16950
KORT: +82 316272800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
138
Stocks News & Analysis
stocks
Are declining Chinese births a red flag for A2 Milk?
Demographic challenges in A2’s largest market lead to sell-off.
stocks
Is this ASX share a value trap or bargain?
Cost-cutting the priority as underlying asset values falling on deaf ears.
stocks
Goldman Sachs Earnings: Valuations remain stretched
We raise our fair value estimate for Goldman Sachs stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,108.60 | 16.20 | 0.18% |
| CAC 40 | 8,058.91 | 3.67 | -0.05% |
| DAX 40 | 24,641.04 | 62.08 | -0.25% |
| Dow JONES (US) | 48,488.59 | 870.74 | -1.76% |
| FTSE 100 | 10,125.32 | 1.46 | -0.01% |
| HKSE | 26,585.06 | 97.55 | 0.37% |
| NASDAQ | 22,954.32 | 561.07 | -2.39% |
| Nikkei 225 | 52,774.64 | 216.46 | -0.41% |
| NZX 50 Index | 13,417.17 | 156.76 | -1.15% |
| S&P 500 | 6,796.86 | 143.15 | -2.06% |
| S&P/ASX 200 | 8,782.90 | 14.00 | 0.16% |
| SSE Composite Index | 4,116.94 | 3.29 | 0.08% |